Brahmer, J. R., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Zhang, J., Lubiniecki, G. M., Deitz, A. C., Rangwala, R., & Reck, M. (n.d.). health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. Lancet oncology, 18(12), 1600–1609. http://access.bl.uk/ark:/81055/vdc_100054259300.0x00000c